苏瑞开地 | 85053-46-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苏瑞开地
• 中文别名: 舒立卡尼
• 英文名称: Suricainide
• 英文别名: 1-[2-(benzenesulfonyl)ethyl]-3-[2-(diethylamino)ethyl]-1-propan-2-ylurea
• CAS: 85053-46-9
• 化学式: C₁₈H₃₁N₃O₃S
• 分子量: 369.5
• InChiKey: OSTGVQSWUXGHKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• N-(arylthioalkyl)-N'-(aminoalkyl)ureas
  申请人：A.H. ROBINS COMPANY, INCORPORATED

  公开号：EP0066415A2

  公开（公告）日：1982-12-08

  N-(Arylthioalkyl)-N'-(aminoalkyl)ureas and thioureas and oxidation derivatives having the formula wherein B represents a thio, sulphinyl or sulphonyl group; R1 and R2 each represent a hydrogen atom or a loweralkyl, cycloalkyl, 2-furanyl, phenyl, substituted phenyl or phenyl-loweralkyl group and R3 and R4 each represent a hydrogen atom or a loweralkyl, phenyl or phenyl-loweralkyl group wherein phenyl is optionally substituted, or R3 and R4 taken with the adjacent nitrogen form a heterocyclic residue.

  N-(芳硫基)-N'-(氨基烷基)脲类和硫脲类及氧化衍生物，其式为 其中 B 代表硫代、亚砜基或磺酰基；R1 和 R2 各代表一个氢原子或低级烷基、环烷基、2-呋喃基、苯基、取代苯基或苯基-低级烷基，R3 和 R4 各代表一个氢原子或低级烷基、苯基或苯基-低级烷基，其中苯基任选被取代，或 R3 和 R4 与相邻的氮形成杂环残基。
• LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3502130A1

  公开（公告）日：2019-06-26

  Disclosed is a ligand regulated protein-protein interaction system based on a lipocalin-fold molecule comprising: (a) a lipocalin-fold molecule (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below, and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand, and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 µM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.

  所公开的是一种基于脂钙蛋白折叠分子的配体调节蛋白质-蛋白质相互作用系统，该系统包括 (a) 脂钙蛋白折叠分子 (b) 低分子量为 1500 Da 或以下的脂钙蛋白-折叠配体，以及 (c) 脂钙蛋白-折叠结合相互作用伙伴、 其中脂钙素折叠分子可与脂钙素折叠配体结合；以及 其中与脂钙蛋白配体结合的脂钙蛋白-折叠分子与脂钙蛋白-折叠结合相互作用伙伴结合的亲和力比未与脂钙蛋白-折叠配体结合的脂钙蛋白-折叠分子的亲和力至少高 10 倍、 其中脂钙蛋白-折叠结合相互作用伙伴不是天然存在的蛋白质，它在任何脂钙蛋白-折叠配体存在下对任何天然存在的脂钙蛋白-折叠分子的亲和力小于10 µM。
• DHA-PHARMACEUTICAL AGENT CONJUGATES
  申请人：Neuromedica, Inc.

  公开号：EP0909183A2

  公开（公告）日：1999-04-21